tenofovir 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antivirals phosphonic acid derivatives	2592	147127-20-6

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: tenofovir hydrate tenofovir tenefovir	An adenine analog REVERSE TRANSCRIPTASE INHIBITOR with antiviral activity against HIV-1 and HEPATITIS B. It is used to treat HIV INFECTIONS and CHRONIC HEPATITIS B, in combination with other ANTIVIRAL AGENTS, due to the emergence of ANTIVIRAL DRUG RESISTANCE when it is used alone. Molecular weight: 287.22 Formula: C9H14N5O4P CLOGP: -1.16 LIPINSKI: 0 HAC: 9 HDO: 3 TPSA: 136.38 ALOGS: -2.19 ROTB: 5 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

tenofovir hydrate
tenofovir
tenefovir

An adenine analog REVERSE TRANSCRIPTASE INHIBITOR with antiviral activity against HIV-1 and HEPATITIS B. It is used to treat HIV INFECTIONS and CHRONIC HEPATITIS B, in combination with other ANTIVIRAL AGENTS, due to the emergence of ANTIVIRAL DRUG RESISTANCE when it is used alone.

Molecular weight: 287.22
Formula: C9H14N5O4P
CLOGP: -1.16
LIPINSKI: 0
HAC: 9
HDO: 3
TPSA: 136.38
ALOGS: -2.19
ROTB: 5

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

None

ADMET properties:

Property	Value	Reference
BA (Bioavailability)	25 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	0.83 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	3.10 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.93 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	5.80 hours	Lombardo F, Berellini G, Obach RS
S (Water solubility)	2 mg/mL	Bocci G, Oprea TI, Benet LZ
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Bocci G, Oprea TI, Benet LZ

Approvals:

Date	Agency	Company	Orphan
Nov. 5, 2009	FDA	HETERO DRUGS LTD
March 25, 2004	PMDA	Japan Tobacco Inc.

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Maternal exposure during pregnancy	219.60	30.98	128	2555	219934	63266405
Drug resistance	140.71	30.98	48	2635	22885	63463454
Rebound effect	122.02	30.98	30	2653	4496	63481843
Virologic failure	119.22	30.98	25	2658	1837	63484502
Foetal exposure during pregnancy	118.01	30.98	46	2637	31916	63454423
Exposure during pregnancy	102.91	30.98	70	2613	155477	63330862
Drug interaction	99.55	30.98	80	2603	229051	63257288
Immune reconstitution inflammatory syndrome	99.05	30.98	27	2656	6057	63480282
Fanconi syndrome acquired	96.50	30.98	19	2664	1017	63485322
Viral mutation identified	91.48	30.98	20	2663	1790	63484549
Abortion spontaneous	82.21	30.98	40	2643	47155	63439184
Hepatitis B	76.67	30.98	20	2663	3792	63482547
Fanconi syndrome	68.22	30.98	15	2668	1377	63484962
Pathogen resistance	62.13	30.98	19	2664	6379	63479960
Premature delivery	56.73	30.98	27	2656	30254	63456085
Hypophosphataemic osteomalacia	52.90	30.98	9	2674	211	63486128
Congenital umbilical hernia	49.73	30.98	9	2674	304	63486035
Blood HIV RNA increased	47.74	30.98	10	2673	729	63485610
Birth mark	47.38	30.98	8	2675	179	63486160
Autoimmune hepatitis	45.13	30.98	16	2667	8494	63477845
Caesarean section	43.97	30.98	19	2664	17013	63469326
Immune reconstitution inflammatory syndrome associated tuberculosis	41.93	30.98	8	2675	362	63485977
Renal tubular dysfunction	40.64	30.98	8	2675	427	63485912
Hydrops foetalis	37.97	30.98	8	2675	600	63485739
Glycosuria	37.93	30.98	9	2674	1157	63485182
Treatment noncompliance	37.63	30.98	22	2661	37303	63449036
Ergot poisoning	37.50	30.98	6	2677	95	63486244
Glucocorticoids increased	35.90	30.98	6	2677	126	63486213
Stillbirth	33.18	30.98	12	2671	6738	63479601
Ultrasound antenatal screen	32.67	30.98	6	2677	220	63486119
Nephropathy toxic	32.67	30.98	13	2670	9466	63476873
Abortion induced	31.69	30.98	13	2670	10229	63476110
Hereditary optic atrophy	31.28	30.98	4	2679	10	63486329

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Psychiatric decompensation	371.98	22.23	88	5610	2849	34948384
Depression suicidal	311.67	22.23	74	5624	2431	34948802
Tearfulness	307.06	22.23	74	5624	2593	34948640
Depressive symptom	256.80	22.23	65	5633	2794	34948439
Immune reconstitution inflammatory syndrome	256.22	22.23	83	5615	8676	34942557
Psychomotor skills impaired	222.84	22.23	62	5636	3844	34947389
Paranoia	196.86	22.23	74	5624	11994	34939239
Lipodystrophy acquired	185.80	22.23	52	5646	3292	34947941
Mitochondrial toxicity	177.87	22.23	48	5650	2651	34948582
Drug interaction	174.18	22.23	198	5500	225748	34725485
Psychotic disorder	170.49	22.23	82	5616	24370	34926863
Progressive external ophthalmoplegia	166.04	22.23	40	5658	1395	34949838
Retinal toxicity	145.21	22.23	29	5669	411	34950822
Suicidal ideation	126.86	22.23	80	5618	40308	34910925
Eyelid ptosis	122.49	22.23	43	5655	5723	34945510
Hepatitis B	120.94	22.23	43	5655	5940	34945293
Psychomotor retardation	120.68	22.23	38	5660	3612	34947621
Acquired gene mutation	117.64	22.23	30	5668	1325	34949908
Foetal exposure during pregnancy	103.70	22.23	69	5629	38032	34913201
Fanconi syndrome acquired	97.20	22.23	28	5670	1963	34949270
Drug resistance	90.59	22.23	55	5643	25872	34925361
Diplopia	80.96	22.23	44	5654	16799	34934434
Anxiety	75.85	22.23	87	5611	99341	34851892
Pathogen resistance	75.84	22.23	35	5663	9447	34941786
Hepatic failure	67.21	22.23	51	5647	34480	34916753
Ophthalmoplegia	64.33	22.23	20	5678	1820	34949413
Ultrasound antenatal screen	56.67	22.23	14	5684	542	34950691
Gene mutation	56.44	22.23	17	5681	1391	34949842
Trisomy 18	52.13	22.23	14	5684	757	34950476
Hydrops foetalis	50.50	22.23	14	5684	853	34950380
Cleft lip and palate	49.80	22.23	14	5684	898	34950335
Drug-induced liver injury	46.22	22.23	38	5660	28794	34922439
Congenital umbilical hernia	43.13	22.23	10	5688	294	34950939
Birth mark	43.08	22.23	9	5689	161	34951072
Hepatitis B reactivation	42.88	22.23	18	5680	3873	34947360
Adrenal suppression	40.24	22.23	11	5687	636	34950597
Night blindness	39.77	22.23	9	5689	237	34950996
Superior mesenteric artery syndrome	36.04	22.23	7	5691	85	34951148
Depression	34.63	22.23	59	5639	97039	34854194
Volvulus	33.99	22.23	12	5686	1620	34949613
Fanconi syndrome	33.37	22.23	12	5686	1708	34949525
Nephropathy toxic	32.28	22.23	22	5676	12566	34938667
Mitochondrial myopathy	30.45	22.23	7	5691	198	34951035
Portal hypertension	29.40	22.23	14	5684	4048	34947185
Hepatocellular carcinoma	28.98	22.23	17	5681	7492	34943741
Osteomalacia	28.04	22.23	9	5689	908	34950325
Hepatic encephalopathy	27.03	22.23	21	5677	14664	34936569
Brachydactyly	25.30	22.23	6	5692	195	34951038
Renal tubular dysfunction	25.27	22.23	7	5691	425	34950808
Viral mutation identified	23.91	22.23	11	5687	2943	34948290
BRASH syndrome	23.65	22.23	7	5691	539	34950694
Osteoporotic fracture	22.61	22.23	8	5690	1087	34950146

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Immune reconstitution inflammatory syndrome	380.18	20.71	111	7695	13730	79722852
Psychiatric decompensation	379.37	20.71	86	7720	3877	79732705
Depression suicidal	312.31	20.71	73	7733	3769	79732813
Tearfulness	279.44	20.71	73	7733	5972	79730610
Drug interaction	245.82	20.71	249	7557	414934	79321648
Depressive symptom	242.05	20.71	66	7740	6357	79730225
Psychomotor skills impaired	231.27	20.71	61	7745	5176	79731406
Hepatitis B	216.29	20.71	64	7742	8268	79728314
Paranoia	195.49	20.71	73	7733	19359	79717223
Mitochondrial toxicity	190.24	20.71	47	7759	3067	79733515
Lipodystrophy acquired	189.16	20.71	50	7756	4275	79732307
Progressive external ophthalmoplegia	186.03	20.71	40	7766	1405	79735177
Psychotic disorder	175.10	20.71	84	7722	41318	79695264
Drug resistance	173.55	20.71	84	7722	42129	79694453
Retinal toxicity	147.92	20.71	33	7773	1378	79735204
Fanconi syndrome acquired	146.27	20.71	37	7769	2657	79733925
Pathogen resistance	141.02	20.71	53	7753	14289	79722293
Acquired gene mutation	137.89	20.71	34	7772	2199	79734383
Maternal exposure during pregnancy	129.51	20.71	107	7699	136431	79600151
Psychomotor retardation	115.87	20.71	37	7769	6147	79730435
Suicidal ideation	115.10	20.71	79	7727	76261	79660321
Eyelid ptosis	112.90	20.71	42	7764	11002	79725580
Fanconi syndrome	96.73	20.71	27	7779	2829	79733753
Viral mutation identified	92.99	20.71	28	7778	3830	79732752
Rebound effect	90.75	20.71	32	7774	7194	79729388
Ultrasound antenatal screen	88.16	20.71	19	7787	674	79735908
Hydrops foetalis	75.03	20.71	17	7789	761	79735821
Diplopia	71.09	20.71	43	7763	33423	79703159
Trisomy 18	67.99	20.71	15	7791	594	79735988
Gene mutation	66.92	20.71	20	7786	2666	79733916
Cleft lip and palate	65.96	20.71	15	7791	683	79735899
Hepatitis B reactivation	65.25	20.71	24	7782	6084	79730498
Hepatic failure	64.33	20.71	51	7755	61161	79675421
Virologic failure	62.08	20.71	21	7785	4170	79732412
Ophthalmoplegia	61.10	20.71	19	7787	2893	79733689
Nephropathy toxic	58.80	20.71	32	7774	20387	79716195
Abortion spontaneous	55.27	20.71	35	7771	29472	79707110
Drug-induced liver injury	52.76	20.71	47	7759	66070	79670512
CSF HIV escape syndrome	52.63	20.71	11	7795	336	79736246
Anxiety	52.35	20.71	90	7716	248422	79488160
Foetal exposure during pregnancy	51.86	20.71	20	7786	5770	79730812
Hypophosphataemic osteomalacia	46.52	20.71	10	7796	350	79736232
Adrenal suppression	46.34	20.71	13	7793	1386	79735196
Exposure during pregnancy	45.94	20.71	53	7753	101079	79635503
Blood HIV RNA increased	43.04	20.71	13	7793	1795	79734787
Night blindness	42.07	20.71	10	7796	553	79736029
Portal hypertension	41.27	20.71	18	7788	7090	79729492
Glycosuria	40.60	20.71	13	7793	2175	79734407
Renal tubular dysfunction	38.87	20.71	10	7796	767	79735815
Hepatic encephalopathy	38.73	20.71	26	7780	24140	79712442
Hypophosphataemia	38.24	20.71	24	7782	19889	79716693
Immune reconstitution inflammatory syndrome associated tuberculosis	38.15	20.71	10	7796	826	79735756
Caesarean section	37.07	20.71	20	7786	12515	79724067
Osteomalacia	36.78	20.71	11	7795	1469	79735113
Superior mesenteric artery syndrome	34.46	20.71	7	7799	185	79736397
Hepatocellular carcinoma	34.18	20.71	17	7789	9004	79727578
Mitochondrial myopathy	31.42	20.71	7	7799	290	79736292
Glucocorticoids increased	30.77	20.71	6	7800	128	79736454
Hereditary optic atrophy	30.41	20.71	5	7801	38	79736544
Ergot poisoning	30.38	20.71	6	7800	137	79736445
Hepatic cirrhosis	30.21	20.71	26	7780	34880	79701702
Treatment noncompliance	26.46	20.71	29	7777	52239	79684343
Malaise	25.73	20.71	8	7798	489861	79246721
Hepatic cytolysis	25.09	20.71	21	7785	27130	79709452
Autoimmune hepatitis	24.65	20.71	15	7791	11768	79724814
Renal tubular necrosis	24.46	20.71	20	7786	25019	79711563
Renal impairment	24.26	20.71	50	7756	157733	79578849
Meningitis cryptococcal	24.07	20.71	10	7796	3496	79733086
Renal tubular acidosis	23.78	20.71	10	7796	3604	79732978
BRASH syndrome	22.87	20.71	7	7799	1010	79735572
Depression	22.64	20.71	59	7747	216731	79519851
Viral load increased	22.25	20.71	9	7797	2939	79733643
HIV infection	22.17	20.71	7	7799	1120	79735462
Pain	21.92	20.71	22	7784	703780	79032802
Unmasking of previously unidentified disease	21.66	20.71	8	7798	2049	79734533
Premature delivery	21.37	20.71	18	7788	23449	79713133
Secondary syphilis	21.32	20.71	4	7802	69	79736513
Oligohydramnios	20.98	20.71	9	7797	3403	79733179

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
MeSH PA	D019380	Anti-HIV Agents
MeSH PA	D000890	Anti-Infective Agents
MeSH PA	D044966	Anti-Retroviral Agents
MeSH PA	D000998	Antiviral Agents
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D019384	Nucleic Acid Synthesis Inhibitors
MeSH PA	D018894	Reverse Transcriptase Inhibitors
CHEBI has role	CHEBI:36044	antiviral drugs
CHEBI has role	CHEBI:49103	drug metabolites
CHEBI has role	CHEBI:53756	reverse transcriptase inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Chronic type B viral hepatitis	indication	61977001
Human immunodeficiency virus infection	indication	86406008	DOID:526
Coronavirus infection	off-label use	186747009
Prevention of HIV Infection after Exposure	off-label use
Osteomalacia	contraindication	4598005	DOID:10573
Hypophosphatemia	contraindication	4996001
Suicidal thoughts	contraindication	6471006
Hypercholesterolemia	contraindication	13644009
Torsades de pointes	contraindication	31722008
Depressive disorder	contraindication	35489007
Fanconi syndrome	contraindication	40488004	DOID:1062
Acute nephropathy	contraindication	58574008
Hepatic failure	contraindication	59927004
Aggressive behavior	contraindication	61372001
Kidney disease	contraindication	90708001	DOID:557
Lactic acidosis	contraindication	91273001	DOID:3650
Prolonged QT interval	contraindication	111975006
Chronic hepatitis C	contraindication	128302006
Seizure disorder	contraindication	128613002
Liver function tests abnormal	contraindication	166603001
Paranoid disorder	contraindication	191667009
Steatosis of liver	contraindication	197321007
Mania	contraindication	231494001
Disease of liver	contraindication	235856003	DOID:409
Pathological fracture	contraindication	268029009
Pregnancy, function	contraindication	289908002
Hypertriglyceridemia	contraindication	302870006
Severe depression	contraindication	310497006
Osteopenia	contraindication	312894000
Breastfeeding (mother)	contraindication	413712001
Obesity	contraindication	414916001	DOID:9970
Congenital long QT syndrome	contraindication	442917000

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	0.23	acidic
pKa2	4.92	acidic
pKa3	4.28	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	UniProt	Type	Activity value (-log[M])	Bioact source
Reverse transcriptase/RNaseH	Enzyme	Q72547_9HIV1	IC50	6.42	CHEMBL
Reverse transcriptase	Enzyme	Q9WKE8_9HIV1	IC50	6.42	CHEMBL
Capsid protein	Unclassified	Q03732_HBV	EC50	6.62	CHEMBL

External reference:

ID	Source
4021279	VUID
N0000148716	NUI
D06074	KEGG_DRUG
4021279	VANDF
C0384228	UMLSCUI
CHEBI:63625	CHEBI
TFO	PDB_CHEM_ID
CHEMBL3989702	ChEMBL_ID
CHEMBL483	ChEMBL_ID
CHEMBL1486	ChEMBL_ID
DB14126	DRUGBANK_ID
D000068698	MESH_DESCRIPTOR_UI
464205	PUBCHEM_CID
10948	IUPHAR_LIGAND_ID
99YXE507IL	UNII
117466	RXNORM
d04774	MMSL
009357	NDDF
395264002	SNOMEDCT_US
422091007	SNOMEDCT_US
206184-49-8	SECONDARY_CAS_RN

Pharmaceutical products:

None